OKYO Pharma Limited (OKYO)
USD 1.07
(0.94%)
USD 1.07
(0.94%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 7506.16 | 3797.00 | 2423.01 | 13.08 Thousand | 5971.08 | 219.17 |
| Gross Profit | -7506.16 | -3797.00 | -2423.01 | -13.08 Thousand | -5971.08 | -219.17 |
| Operating Expenses | 8243.57 | 13.18 Million | 6.21 Million | 3.36 Million | 1.51 Million | 4.53 Million |
| Selling, General and Administrative Expenses | - | 6.74 Million | 4.92 Million | 2.97 Million | 995.42 Thousand | 1.85 Million |
| Research and Development Expenses | 8243.57 | 6.33 Million | 1.6 Million | 348.34 Thousand | 517.45 Thousand | 3.04 Million |
| Other Expenses | - | - | - | - | - | -15.81 Thousand |
| Cost and Expenses | 15.74 Thousand | 13.18 Million | 6.21 Million | 3.36 Million | 1.51 Million | 4.53 Million |
| Operating Income | -15.74 Thousand | -13.18 Million | -6.21 Million | -4.13 Million | -1.51 Million | -4.53 Million |
| Interest Expense | 1.05 Million | 96.68 Thousand | - | 1123.00 | 1156.88 | - |
| Income Tax Expense | 22.42 | -12.2 Thousand | -786.52 Thousand | -24.99 Thousand | -76.19 Thousand | -171.64 Thousand |
| Earnings before Tax | -16.8 Thousand | -13.28 Million | -6.21 Million | -3.37 Million | -1.61 Million | -4.9 Million |
| Net Income | -16.82 Thousand | -13.27 Million | -5.43 Million | -3.35 Million | -1.54 Million | -4.9 Million |
| Earnings Per Share Basic | -0.00 | -0.60 | -0.01 | -0.01 | -0.00 | -0.01 |
| Earnings Per Share Diluted | -0.00 | -0.60 | -0.01 | -0.01 | -0.00 | -0.01 |
| Weighted Average Shares Outstanding | 29.34 Million | 22.25 Million | 979.21 Million | 672.76 Million | 595.47 Million | 513.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.34 Million | 22.25 Million | 979.21 Million | 672.76 Million | 595.47 Million | 513.9 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -15.74 Thousand | -13.18 Million | -6.21 Million | -3.35 Million | -1.51 Million | -4.53 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 FY | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 3866.00 | - | 3797.00 | 1932.20 | 1971.10 | 1661.94 |
| Gross Profit | -3866.00 | - | -3797.00 | -1932.20 | -1971.10 | -1661.94 |
| Operating Expenses | 15.69 Million | - | 13.18 Million | 1843.53 | 1878.07 | 5.54 Million |
| Selling, General and Administrative Expenses | - | - | - | - | - | 2.94 Million |
| Research and Development Expenses | - | - | - | 1843.53 | 1878.07 | 2.59 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 15.69 Million | - | 13.18 Million | 3775.73 | 3849.17 | 5.54 Million |
| Operating Income | -15.69 Million | - | -13.18 Million | -3775.73 | -3849.17 | -5.54 Million |
| Interest Expense | 1.05 Million | - | 96.68 Thousand | - | - | - |
| Income Tax Expense | 22.41 Thousand | - | -12.2 Thousand | 6.10 | 6.10 | -2.94 |
| Earnings before Tax | -16.8 Million | - | -13.28 Million | -3824.08 | -3897.52 | -5.52 Million |
| Net Income | -16.82 Million | - | -13.27 Million | -3817.98 | -3891.41 | -5.52 Million |
| Earnings Per Share Basic | - | - | - | -0.17 | -0.17 | -0.00 |
| Earnings Per Share Diluted | - | - | - | -0.17 | -0.17 | -0.00 |
| Weighted Average Shares Outstanding | 29.34 Million | - | 22.25 Million | 22.87 Thousand | 22.87 Thousand | 1.4 Billion |
| Weighted Average Shares Outstanding (Diluted) | 29.34 Million | - | 22.25 Million | 22.87 Thousand | 22.87 Thousand | 1.4 Billion |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | -3774.68 | -3848.10 | -5.54 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
FAS
OCX
0JTQ
NGIL
PANAMAPET
3485